A Safety and Efficacy Study of Xolair in Peanut Allergy

Stopped early · Phase 2

Conditions studied: Allergy

In brief

This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.

Key facts

Study ID

NCT00086606

Run by

Genentech, Inc.

People needed

150

Starts

2004-06-01

Expected to finish

2006-04-01

Last updated by the study team

2013-01-21

Who can join

Age: 6 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient has a diagnosis of acute peanut allergy
• The patient meets the Xolair dosing table eligibility criteria by having a serum baseline IgE level between 30 and 1300IU/mL, and a body weight between 20 and 150 kilograms
• The patient is six to 75 years of age
• The patient reacts to peanut flour but not wheat (placebo) flour during the first Oral Food Challenge (OFC)
• The patient has a positive skin prick test to peanut or detectable serum peanut-specific IgE level
• The patient is able to swallow capsules

You may not qualify if…

• Have FEV1 value <80% predicted or any clinical features of moderate persistent asthma, as defined by the NHLBI guidelines
• Have other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders), which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions
• Have a history of allergy to wheat protein
• Have previously been exposed to monoclonal antibody treatment

Where it is running

• Trial Information Support Line — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.